Skip to content

Evaluation of the Efficacy of Short-term Noni Herbal Supplement in Subjects with Diabetes mellitus

An open-label two-cohort study of efficacy of Noni Herbal Supplement in improving glucose control in patients with diabetes mellitus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/04/001697
Enrollment
60
Registered
2011-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Diabetes Mellitus : Type 1 and Type 2

Interventions

Intervention1: Noni Whole Fruit freeze-dried powder provided as a single-use sachet: Noni 3.3 grams powder given twice daily on empty stomach for 12 weeks Control Intervention1: Diabetic patients not

Sponsors

Surya Herbal Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Men and women ≥25 years of age Written informed consent from the subject. A diagnosis of diabetes either type 1 or type 2.

Exclusion criteria

Exclusion criteria: 1. Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening. 2. Subjects participating in any other clinical trial or herbal supplement investigation. 3. Subjects on any other herbal therapy / supplement for diabetes 4. Uncontrolled diabetes mellitus (known hemoglobin A1c [HbA1c] 12% within the last 1 month prior to Screening) 5. Subjects living too far from the participating center or unable to return for follow-up visits 6. Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk for therapy with an investigational supplement, are unreliable, or have an incomplete understanding of the study which may affect their ability to take the supplement as prescribed or comply with instructions 7. Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), or tuberculosis infection 8. Acute bacterial, fungal or viral infection 9. Women who are pregnant or are planning for pregnancy. 10. Any diabetics who have concomitant chronic renal failure or chronic heart failure.

Design outcomes

Primary

MeasureTime frame
To determine whether 12 weeks of dietary supplementation with Noni along with the standard of care is superior to standard of care alone for improving glucose control among diabetics.Timepoint: 12 weeks

Secondary

MeasureTime frame
1. To assess if the requirement of glucose-lowering medication would be reduced following the 12 - week supplementation with Noni in diabetic subjects. 2. To determine any side effects that may occur as part of the Noni dietary supplement.Timepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Prem Anand Nagaraja
drprem.nagaraja@gmail.com080-27835000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026